<DOC>
	<DOCNO>NCT01075828</DOCNO>
	<brief_summary>After consultation Korean Health Authorities , two Post-Authorization Safety Studies EMR 62202-509 ( NCT01082315 ) EMR 62241-508 ( NCT01075828 ) combine within one study protocol EMR 062202-551 . This Post-Marketing Surveillance Study ( PMS ) EMR 062202-551 requested Korean Health Authorities continue monitor Erbitux provide information safety toxicity clinical practice least 900 patient 6 year . All data point EMR 62202-509 ( NCT01082315 ) EMR 62241-508 ( NCT01075828 ) remain unchanged protocol EMR 062202-551 . Therefore , Sponsor decide separately disclose EMR 062202-551 study title `` A Korean Post-Marketing Surveillance Study On Erbitux® ( Cetuximab ) Patients With Locally Advanced Recurrent and/or Metastatic Squamous Cell Cancer Head Neck ( originally EMR 62241-508 ) Patients With EGFR-expressing , KRAS wild-type Metastatic Colorectal Cancer ( originally EMR 62202-509 ) '' clinicaltrials.gov .</brief_summary>
	<brief_title>Prospective , Post Marketing Surveillance Study On Erbitux® ( Cetuximab ) Patients With Locally Advanced Recurrent and/or Metastatic Squamous Cell Cancer Head Neck Korea</brief_title>
	<detailed_description>This prospective , Post Marketing Surveillance ( PMS ) study Erbitux® ( Cetuximab ) patient locally advanced recurrent and/or metastatic squamous cell cancer head neck Korea This prospective study collect safety information 300 subject treat Erbitux final evaluable case . During PMS period , subject background , subject 's medical ( surgery , anti-cancer treatment ) history , Erbitux treatment status , concurrent medication , response evaluation , status reason discontinuation , adverse event ( AEs ; regardless causal relationship Erbitux ) , abnormal result laboratory test collect study purpose . The PMS base case treat Erbitux least . The PMS do within 6 year approval date new indication . This PMS request Korean Regulatory Authorities . After approval new indication Korea , require investigate 300 subject 6 year accord local regulation continue monitor provide information safety toxicity clinical practice . OBJECTIVES Analysis safety efficacy information use Erbitux market factor affect safety efficacy . Primary objective : - To obtain safety information use Erbitux subject locally advanced SCCHN recurrent and/or metastatic term frequency severity AEs Secondary objective : - To gather clinical efficacy information treatment</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Subjects eligible Erbitux treatment accord indication national label Erbitux . The national label approve Korea Food &amp; Drug Administration `` Erbitux combination radiation therapy indicate treatment subject locally advance recurrent and/or metastatic SCCHN Subjects eligible Erbitux treatment accord indication national label Erbitux</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Head Neck Neoplasms</keyword>
	<keyword>Neoplasms , Squamous Cell</keyword>
	<keyword>Cetuximab</keyword>
</DOC>